Elsevier

Clinical Biochemistry

Volume 30, Issue 1, February 1997, Pages 53-56
Clinical Biochemistry

Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: Special emphasis on “spiking” phenomena

https://doi.org/10.1016/S0009-9120(96)00133-6Get rights and content

Abstract

Objectives: CA 15-3 and CEA are considered useful tumor markers in monitoring breast cancer patients. This study was undertaken to specifically evaluate the transient elevations in these markers that are observed during systemic treatment for metastatic disease. This phenomenon has been termed “spiking.”

Design and Methods: Serum tumor marker levels were investigated by enzyme immunoassay in 20 breast cancer patients without metastases and in 20 patients with bone metastases receiving systemic treatment.

Results: Both CEA and CA 15-3 levels were significantly elevated in the patients with bone metastases. Serum CEA and CA 15-3 levels in patients with metastases displayed a transient, but significant, elevation days 15 and 30, respectively, after commencing systemic treatment, which returned to pretreatment levels on the 60th day.

Conclusions: The spiking effect observed in the tumor marker levels should be carefully evaluated, and not be misdiagnosed as disease progression.

References (16)

  • E. Bombardieri et al.

    CA 15-3 determination in patients with breast cancer: Clinical utility for the detection of distant metastases

    Eur J Cancer

    (1993)
  • S.E. Bates et al.

    Use of serum tumor markers in cancer diagnosis and management

    Semin Oncol

    (1987)
  • M.L. Lüthgens et al.

    Clinical cancer markers

  • F.J.F. Liu

    Serum tumor marker assays in cancer patient care

    Cancer Bull

    (1993)
  • I. Roisman et al.

    The significance of the CA 15-3 breast tumor marker as an additional tool for detection of breast cancer

    J Tumor Marker Oncol

    (1994)
  • M. Eskelinen et al.

    Use of tumor markers CA 15-3, MCA and CEA in breast cancer diagnostics

    J Tumor Marker Oncol

    (1989)
  • J. Hilkens

    CA 15-3 Assay for the detection of episialin

  • D.F. Hayes et al.

    Clinical Applications of CA 15-3

There are more references available in the full text version of this article.

Cited by (0)

View full text